Clinical Trials
| Merck 2214 | |
| Therapeutic Area Name | Neurosciences |
| Condition or Disease | Early Alzheimer's Disease |
| Title | A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease |
| Study ID | Merck 2214 |
| Principal Investigator First Name | Concetta |
| Principal Investigator Last Name | Forchetti |
| Clinicaltrials.gov | Pending |